$66.26 0.5 0.8%
Last Trade - 22/04/21
| Market Cap | £2.31bn |
| Enterprise Value | £1.81bn |
| Revenue | £15.7m |
| Position in Universe | 1809th / 6852 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 6.67 | 7.58 | 14.3 | 43.0 | 21.8 | 15.3 | 12.6 | +34.5% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Arvinas, Inc., formerly Arvinas Holding Co LLC, is a development staged biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to degrade disease-causing proteins. The Company uses its technology platform to engineer proteolysis targeting chimeras (PROTACs), which are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The Company is using its PROTAC platform to build an pipeline of protein degradation product candidates to target diseases in a wide range of organ systems and tissues. It is also focused on advancing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. It seeks to initiate a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer (mCRPC), and a Phase 1 clinical trial for ARV-471 in women with metastatic ER positive, HER2 negative breast cancer, or ER+ breast cancer.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | December 9, 2014 |
| Public Since | September 27, 2018 |
| No. of Shareholders: | 83 |
| No. of Employees: | 179 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 48,874,027 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 5 Science Park, NEW HAVEN, 06511-1966, United States |
| Web | http://arvinas.com/ |
| Phone | +1 203 5351456 |
| Contact | () |
| Auditors | Deloitte & Touche LLP |
As of 22/04/21, shares in Arvinas Inc are trading at $66.26, giving the company a market capitalisation of £2.31bn. This share price information is delayed by 15 minutes.
Shares in Arvinas Inc are currently trading at $66.26 and the price has moved by 29.34% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arvinas Inc price has moved by -12.44% over the past year.
Of the analysts with advisory recommendations for Arvinas Inc, there are there are currently 4 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Arvinas Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Arvinas Inc is scheduled to issue upcoming financial results on the following dates:
Arvinas Inc does not currently pay a dividend.
Arvinas Inc does not currently pay a dividend.
Arvinas Inc does not currently pay a dividend.
To buy shares in Arvinas Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Arvinas Inc are currently trading at $66.26, giving the company a market capitalisation of £2.31bn.
Here are the trading details for Arvinas Inc:
Based on an overall assessment of its quality, value and momentum, Arvinas Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Arvinas Inc are currently priced at $66.26. At that level they are trading at 65.99% discount to the analyst consensus target price of 0.00.
Analysts covering Arvinas Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.486 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arvinas Inc. Over the past six months, the relative strength of its shares against the market has been 0.157k%. At the current price of $66.26, shares in Arvinas Inc are trading at 38.1% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Arvinas Inc.
Arvinas Inc's management team is headed by:
Here are the top five shareholders of Arvinas Inc based on the size of their shareholding:
